HDT Bio
Company

Last deal

$1M

Amount

Grant

Stage

04.10.2023

Date

3

all rounds

$77.45M

Total amount

date founded

Financing round

General

About Company
HDT Bio develops RNA vaccines and therapeutics using LION formulation technology.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2017

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

The company's products cover a range of immunotherapy modalities, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Their mission is to provide cost-effective solutions to unmet medical needs in the fight against infectious diseases and cancers, both in developed and developing countries. Their product lines include self-amplifying RNA vaccines and innate immune agonist therapeutics, which can be administered through multiple routes and have enhanced stability and lyophilization properties. HDT Bio aims to complement existing immunotherapies and address critical unmet medical needs globally.
Contacts

Contact Email

Website URL

Social url

Similar Companies
1000
Immutep

Immutep

Immutep is a global biotechnology company developing immunotherapeutic products for the treatment of cancer and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Sydney NSW 2000, Australia

total rounds

5

total raised

$73.47M
Virometix

Virometix

Virometix develops vaccines and immunotherapeutic drugs for infectious and chronic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

8952 Schlieren, Switzerland

total rounds

6

total raised

$14.33M
ImmuneSensor Therapeutics

ImmuneSensor Therapeutics

ImmuneSensor Therapeutics is a biotech company developing innovative medicines for cancer and autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Dallas, TX, USA

total rounds

2

total raised

$26.1M
Soligenix

Soligenix

Soligenix is a biotechnology company focused on treating rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Princeton, NJ, USA

total rounds

18

total raised

$57.98M

Financials

Funding Rounds
7
3

Number of Funding Rounds

$77.45M

Money Raised

Their latest funding was raised on 04.10.2023. Their latest investor Zoic Capital. Their latest round Grant

Date 
Funding Round 
Investors 
Money Raised 
Lead 
04.10.2023
1
$1M
08.08.2022
1
$1.8M

BLUE KNIGHT

BARDA and JLABS launched BLUE KNIGHT, a joint initiative for biomedical research.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

count Of Investments

2
Medical CBRN Defense Consortium

Medical CBRN Defense Consortium

The Medical CBRN Defense Consortium (MCDC) partners with the US government to develop advanced medical solutions for military personnel.

Sector

Aerospace and Defense

Subsector

Defense

Keywords

Military, Government, Biotechnology

Location

Summerville, SC, USA

count Of Investments

2
US Army

US Army

The U.S. Army offers a wide range of career opportunities and training programs for individuals interested in joining the military.

Sector

Aerospace and Defense

Subsector

Defense

Keywords

Training, Military, Recruiting

count Of Investments

21

count Of Exists

1
Co-Investors
Investors
8
7

Number of lead investors

8

Number of investors

Investor 
Lead 
Round 
Partners 
Zoic Capital

Zoic Capital

Zoic Capital is a venture capital firm focused on early-stage healthcare innovations.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Bellevue, WA, USA

count Of Investments

11
Neal Mody

Neal Mody

I’m obsessed with building great companies and focus on those life sciences that will affect humanity. Early in my career, I was fortunate enough to help scale Ambature, a materials science company in the field of superconductivity. When I started Ambature, I didn’t have any experience in materials science; nevertheless, I operated under the belief that the inventor’s idea was right. Fast forward a few years, by the time I left my role, we created over 200 patents with more than 3,700 unique claims, accounting for more than half patents in the field of superconductivity. After I left Ambature, I wanted to make a more significant impact in life sciences, and ultimately on humanity. Being driven by this social mission, I thought about starting a few companies simultaneously; however, after some back and forth, I ultimately concluded that starting a fund would better allow me to scale my efforts. Through Zoic Capital, my team and I help our portfolio companies and investors: ► Develop large scale inclusive IP development strategy ► Help connect and codevelop deals with potential strategic acquirers We are currently the only US-based venture firm focused solely on investing in the seed stage of Medtech, we go through a rigorous vetting process with each investment opportunity to ensure that: 1. their technological developments represent at least a 10X improvement in the standard of care 2. their technology relies upon scientific mechanisms which are fully supported by published literature, independent trials, and personal observation 3. in most cases, they have unique hardware and IP coupled with unique software 4. the leadership team has the necessary combination of vision and experience to create a transformational company 5. has an initial regulatory approval on a short timeline, typically two to four years If you want to learn more about Zoic, the types of companies we invest in, or if you’d like to talk about the market and feature on my podcast, feel free to get in touch with me via email: [email protected] If you know of an interesting deal for Zoic to look at, feel free to get in touch with my team here: [email protected]

current job

Endless Frontier Labs
Endless Frontier Labs

BLUE KNIGHT

BARDA and JLABS launched BLUE KNIGHT, a joint initiative for biomedical research.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

count Of Investments

2
National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases

NIAID conducts research to prevent and treat infectious and allergic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Bethesda, MD, USA

count Of Investments

99

count Of Exists

3

People

Founders
2
Steven Reed
Steven Reed

Steven Reed

Steve Reed founded Immune Design Corp. in 2008 and served as the Chief Executive Officer through May 2011. He is the founder, President and Chief Scientific Officer of the Infectious Disease Research Institute. He co-founded Corixa Corporation in 1994, where he served as Chief Scientific Officer. In 2005 he founded Dharma Therapeutics Inc., a Seattle biotech developing transdermal delivery systems. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health and is a member of the Vaccine Development Steering Committee of the World Health Organization. Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of adjuvants, vaccines and diagnostics for both cancer and infectious diseases. He has more than 210 published original articles, several book chapters, and holds 101 issued patents for diagnostics, vaccines, and therapeutics for infectious diseases and cancer.

current job

HDT Bio
HDT Bio

organization founded

2

Steven Reed

Christopher Pirie
Christopher Pirie

Christopher Pirie

current job

HDT Bio
HDT Bio

organization founded

3

Christopher Pirie

Employee Profiles
4
Peter Berglund

Peter Berglund

Chief Technology Officer

Darrick Carter

Darrick Carter

Chief Scientific Officer

Christopher Pirie

Christopher Pirie

COO

Steven Reed

Steven Reed

Co-Founder & CEO

Activity

Recent News
1